Business Context and Reporting Period
This Form 8-K is a current report filed by resTORbio, Inc. (not Adicet Bio, Inc.) on March 13, 2018. The filing addresses Item 5.02 regarding the confirmation and approval of 2017 performance bonuses for named executive officers, which were omitted from the company's earlier Form S-1 Registration Statement because the amounts had not yet been determined.
Key Financial Metrics
The filing does not provide company-wide revenue, profit, cash flow, debt, or liquidity metrics. It focuses exclusively on executive compensation data for the fiscal year ended December 31, 2017.
| Executive Officer | Position | 2017 Salary | 2017 Non-Equity Bonus | 2017 Total Compensation |
|---|---|---|---|---|
| Chen Schor | President and CEO | $268,826 | $209,280 | $485,506 |
| Joan Mannick | Chief Medical Officer | $236,035 | $163,665 | $406,184 |
| John McCabe | Vice President, Finance | $47,526 | $15,822 | $549,136 |
Note: John McCabe's total compensation includes $485,474 in Option Awards, which were not included in the non-equity bonus column.
Material Changes
- Compensation Revision: The company is revising the Summary Compensation Table previously filed in its Form S-1 to include the 2017 performance bonuses for its named executive officers.
- Bonus Composition: The 2017 bonuses included annual performance-based amounts and milestone-based payments. Specifically, Chen Schor received $173,280 in annual performance bonuses and $36,000 in milestone bonuses. Joan Mannick received $133,665 in annual performance bonuses and $30,000 in milestone bonuses.
Guidance, Outlook, and Risks
The filing outlines the adoption of the Senior Executive Cash Incentive Bonus Plan effective for fiscal year 2018. Future bonuses will be based on performance targets related to financial and operational measures, including:
- Cash flow (operating and free cash flow)
- Research and development, clinical, and regulatory milestones
- Earnings before interest, taxes, depreciation, and amortization (EBITDA)
- Net income (loss)
- Changes in market price of common stock
- Revenue and operating income
The Compensation Committee retains discretion to adjust award sizes for unforeseen factors beyond management's control. The filing does not contain specific forward-looking financial guidance or risk factors beyond the standard compensation plan terms.
Investor Verification Checklist
- Verify the company name is resTORbio, Inc., as the input metadata incorrectly referenced Adicet Bio, Inc.
- Confirm the total 2017 compensation figures for executives, noting that John McCabe's total includes significant option awards not present for the other officers.
- Review the specific performance milestones achieved in 2017 that triggered the $66,000 in milestone bonuses for Schor and Mannick.
- Monitor future filings for the specific targets set under the new 2018 Senior Executive Cash Incentive Bonus Plan.